Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2007 Dec;6(6):913-24. doi: 10.1586/14760584.6.6.913.

Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.

Author information

1
Medical College of Georgia, Immunology/Immunotherapy Program, MCG Cancer Center, CN-4150, 1120 15th Street, Augusta, GA 30912, USA. yhe@mcg.edu

Abstract

Encouraged by remarkable successes in preventing infectious diseases and by the well-established potential of the immune system for controlling tumor growth, active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, engineered recombinant viral vectors have been carefully examined as genetic-immunization vehicles and have been demonstrated to induce potent T-cell-mediated immune responses that can control tumor growth. Very recent efforts suggest that lentivectors possess important advantages over other candidate recombinant viral vectors for genetic immunization. Here, we review the development of recombinant lentivectors and the characteristics of T-cell immune responses elicited by lentivector immunization, including the mechanism of T-cell priming with a focus on the role of skin dendritic cells and potential applications for tumor immunotherapy.

PMID:
18377355
PMCID:
PMC3065301
DOI:
10.1586/14760584.6.6.913
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center